Interesting overview of healthcare reform on the biologics business in the May edition of Nature Biotechnology. Here's a sample:
"The healthcare reform bill ... includes key provisions that will lead to new and improved treatments, cures and cost-savings for patients, while driving job growth in our industry and maintaining our nation's global leadership in biotech innovation," says Jim Greenwood, president of the Biotechnology Industry Organization (BIO) in Washington, DC. Peter Pitts, president of the Center for Medicine in the Public Interest (CMPI) in New York, agrees: "This legislation will have a huge impact on biotech companies -- the most affected of any industry."
And here's how the article ends:
Says Pitts of CMPI, "Industry lobbied hard for a good bill, but this bill is flawed in so many ways." However, he adds, "It's time to realize that it's no longer just about selling drugs, but for providing healthcare -- and companies must walk the walk."
For the entire article, click here.
"The healthcare reform bill ... includes key provisions that will lead to new and improved treatments, cures and cost-savings for patients, while driving job growth in our industry and maintaining our nation's global leadership in biotech innovation," says Jim Greenwood, president of the Biotechnology Industry Organization (BIO) in Washington, DC. Peter Pitts, president of the Center for Medicine in the Public Interest (CMPI) in New York, agrees: "This legislation will have a huge impact on biotech companies -- the most affected of any industry."
And here's how the article ends:
Says Pitts of CMPI, "Industry lobbied hard for a good bill, but this bill is flawed in so many ways." However, he adds, "It's time to realize that it's no longer just about selling drugs, but for providing healthcare -- and companies must walk the walk."
For the entire article, click here.
